Marc Odrich
Geen lopende functies
Vermogen: 2 M $ op 31-05-2024
Profiel
Marc Odrich is currently the Chief Medical Officer & Director at TearSolutions, Inc., the Director at CXL Ophthalmics LLC, the Chief Medical Officer at LENZ Therapeutics, Inc., and an Associate Professor at the University of Virginia.
He previously worked as the Medical Director at VISX, Inc. Dr. Odrich holds a doctorate degree from Columbia University College of Physicians & Surgeons.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0.39% | 21-03-2024 | 99 599 ( 0.39% ) | 2 M $ | 31-05-2024 |
Actieve functies van Marc Odrich
| Bedrijven | Functie | Begin |
|---|---|---|
TearSolutions, Inc.
 TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Corporate Officer/Principal | - |
CXL Ophthalmics LLC
 CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Directeur/Bestuurslid | - |
| University of Virginia | Corporate Officer/Principal | - |
Eerdere bekende functies van Marc Odrich
| Bedrijven | Functie | Einde |
|---|---|---|
| VISX, Inc. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Marc Odrich
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
TearSolutions, Inc.
TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Health Technology |
CXL Ophthalmics LLC
CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Health Services |
| VISX, Inc. |
